Familial abnormalities of endocannabinoid signaling in schizophrenia

• Verfasst von: Köthe, Dagmar [VerfasserIn]
• Verfasst von: Pahlisch, Franziska [VerfasserIn]
• Verfasst von: Rohleder, Cathrin [VerfasserIn]
• Verfasst von: Meyer-Lindenberg, Andreas [VerfasserIn]
• Verfasst von: Leweke, F. Markus [VerfasserIn]
• Titel: Familial abnormalities of endocannabinoid signaling in schizophrenia
• Verf.angabe: Dagmar Koethe, Franziska Pahlisch, Martin Hellmich, Cathrin Rohleder, Juliane K. Mueller, Andreas Meyer-Lindenberg, E. Fuller Torrey, Daniele Piomelli & F. Markus Leweke
• Jahr: 2019
• Jahr des Originals: 2018
• Umfang: 9 S.
• Fussnoten: Gesehen am 31.05.2019 ; Published online: 22 Mar 2018
• Titel Quelle: Enthalten in: The world journal of biological psychiatry
• Ort Quelle: Abingdon : Taylor & Francis Group, 2000
• Jahr Quelle: 2019
• Band/Heft Quelle: 20(2019), 2, Seite 117-125
• ISSN Quelle: 1814-1412
• DOI: doi:10.1080/15622975.2018.1449966
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: anandamide (AEA)
• Sach-SW: endocannabinoids
• Sach-SW: genetic risk
• Sach-SW: monozygotic twins
• Sach-SW: Psychosis
• K10plus-PPN: 1666557145

Abstract

Objectives: Epidemiological and experimental evidence suggests that the endocannabinoid system plays a pathophysiological role in schizophrenia. This is reflected by elevated cerebrospinal levels of the endocannabinoid anandamide in schizophrenia and its initial prodromal states.Methods: We analyzed plasma concentrations of anandamide, 2-arachidonoyl-sn-glycerol, palmitoylethanolamide and oleoylethanolamide from 25 twin pairs discordant for schizophrenia, six discordant for bipolar disorder and eight healthy twin pairs to determine hereditary traits.Results: Twin pairs discordant for schizophrenia or bipolar disorder had significantly higher levels of anandamide and palmitoylethanolamide compared to healthy twins (both P < 0.002). Non-affected twins discordant for schizophrenia, who developed a psychotic disorder within 5 years follow-up showed lower anandamide (P = 0.042) and 2-arachidonoyl-sn-glycerol levels (P = 0.049) than twins who remained healthy.Conclusions: We suggest that the protective upregulation of endocannabinoid signalling reflects either a hereditary trait or mirrors a modulating response to genetically influenced cerebral function involving, e.g., other neurotransmitters or energy metabolism.